Combination of Tafasitamab/Lenalidomide Demonstrates Positive Efficacy in DLBCL
Development of therapeutic antibodies for the treatment of diseases | Journal of Biomedical Science | Full Text
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study - The Lancet Oncology
Tafasitamab monotherapy vs L-mind regimen in NHL. | Download Scientific Diagram
IJMS | Free Full-Text | Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders | HTML
Advances in targeted therapy for malignant lymphoma | Signal Transduction and Targeted Therapy
Frontiers | CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma | Immunology
![Mode of action of tafasitamab [38]. | Download Scientific Diagram](https://www.researchgate.net/publication/349144244/figure/fig1/AS:1024691787534338@1621316968238/Mode-of-action-of-tafasitamab-38.png "Mode of action of tafasitamab [38]. | Download Scientific Diagram")
Mode of action of tafasitamab [38]. | Download Scientific Diagram
Tafasitamab-cxix (Monjuvi) Drug Information
Diffuse large B-cell lymphoma: new targets and novel therapies | Blood Cancer Journal
![Mode of action of tafasitamab [38]. | Download Scientific Diagram](https://www.researchgate.net/publication/349144244/figure/fig2/AS:1024691787534339@1621316968267/Pharmacokinetics-of-tafasitamab-in-patients-with-R-R-NHL-37_Q320.jpg "Mode of action of tafasitamab [38]. | Download Scientific Diagram")
Mode of action of tafasitamab [38]. | Download Scientific Diagram
Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma | SpringerLink
IJMS | Free Full-Text | Molecular Aspects of Resistance to Immunotherapies—Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma | HTML
Tafasitamab/Lenalidomide Combo Stands Out for Patients With Relapsed/Refractory DLBCL
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma. - Abstract - Europe PMC
Tafasitamab: First Approval | SpringerLink
Combination mechanism of action of tafasitamab and lenalidomide. 41 | Download Scientific Diagram
Novel treatments in B cell non-Hodgkin's lymphomas | The BMJ
Diffuse large B-cell lymphoma: new targets and novel therapies | Blood Cancer Journal
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies | SpringerLink
The use of tafasitamab in diffuse large B-cell lymphoma - Johannes Düll, Max Topp, Gilles Salles, 2021
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress | Journal of Hematology & Oncology | Full Text
Incyte licenses Morphosys' tafasitamab in US$2bn deal - European Biotechnology
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma. - Abstract - Europe PMC
Frontiers | A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions | Immunology
